Image

Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation

Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation

Non Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Critically ill patients who require extracorporeal membrane oxygenation (ECMO) are the sickest in the hospital. More patients are surviving but survivors have compromised functional recovery for months or years. This registry-embedded randomised trial aims to determine if early rehabilitation commenced within 72 hours of ECMO is feasible and improves muscle strength and functional status in patients compared to standard practice in a randomised controlled trial of 100 ICU patients. The effect of the intervention on mortality, health status, and function at 180 days will be evaluated, as well as cost-effectiveness. ECMO-Rehab trial is a registry embedded trial and will be utilising EXCEL data.

Description

The trial is a 100-patient, multicentre, randomised, controlled, parallel-group, two-sided superiority trial that will randomly allocate eligible patients to early rehabilitation or standard care in a 1:1 ratio to determine if early rehabilitation of critically ill patients receiving ECMO reduces disability when compared with standard care. ECMO-Rehab trial is a registry embedded trial and will be utilising EXCEL data.

Eligibility

Inclusion Criteria:

  1. Patient is on ECMO and expected to remain on ECMO for at least 24 hours
  2. Patient is aged 18 years or older.
  3. Patient was functionally independent prior to the current admission.
  4. Patient is eligible for Medicare (Australian sites only).

Exclusion Criteria:

  1. Patient has been receiving ECMO for more than 72 hours.
  2. Patient has been in ICU for more than 5 days.
  3. Patient has suspected or proven primary myopathic or neurological process associated with prolonged weakness or acute brain injury.
  4. Death is deemed imminent by the treating clinician.
  5. Patient has a documented medical diagnosis of cognitive impairment e.g. dementia.
  6. Patient was unable to mobilise prior to this admission.
  7. Patient is unable to communicate in local language.
  8. Patient is known to be pregnant.
  9. Patient is unlikely to be contactable for 6 months follow-up, e.g. overseas resident, incarcerated
  10. The treating clinician does not believe it is in the best interests of the patient to participate in the study
  11. Patient who has a bidirectional cannula in situ

Study details
    Extracorporeal Membrane Oxygenation Complication

NCT05003609

Australian and New Zealand Intensive Care Research Centre

20 August 2025

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.